

NIH BIOGRAPHICAL SKETCH COMMON FORM

Name: Toll, Benjamin

Persistent Identifier (PID) of the Senior/Key Person: <https://orcid.org/0000-0001-7978-8416>

Position Title: Oliver S. and Jennie R. Donaldson Charitable Trust Endowed Chair in Cancer Research

Organization and Location: MUSC Hollings Cancer Center, Charleston, South Carolina, United States

PROFESSIONAL PREPARATION

INSTITUTION AND LOCATION	DEGREE	Start Date	Completion Date	FIELD OF STUDY
Yale University School of Medicine, New Haven, Connecticut, United States	Postdoctoral Psychology Fellowship	09/2002	06/2004	Clinical Psychology Research
Nova Southeastern University, Ft. Lauderdale, Florida, United States	Doctor of Philosophy (PHD)	08/1997	08/2002	Clinical Psychology
Nova Southeastern University, Ft. Lauderdale, Florida, United States	Master of Science (MS)	08/1997	08/1999	Clinical Psychology
Cornell University, Ithaca, New York, United States	Bachelor of Arts (BA)	08/1992	05/1996	Psychology

Appointments and Positions

2025 - present	Oliver S. and Jennie R. Donaldson Charitable Trust Endowed Chair in Cancer Research, MUSC Hollings Cancer Center, Charleston, South Carolina, United States
2025 - present	Oliver S. and Jennie R. Donaldson Charitable Trust Endowed Chair in Cancer Research, MUSC Hollings Cancer Center, Charleston, South Carolina, United States
2025 - present	Oliver S. and Jennie R. Donaldson Charitable Trust Endowed Chair in Cancer Research, MUSC Hollings Cancer Center, Charleston, South Carolina, United States
2021 - present	Associate Director of Education and Training, MUSC Hollings Cancer Center, Charleston, South Carolina, United States
2019 - present	Vice Chair of Research, Department of Public Health Sciences, MUSC, Charleston, South Carolina, United States
2017 - present	Professor with Tenure of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, United States

Products

Products Closely Related to the Proposed Project

1. Fucito LM, Rojewski AM, Tanoue L, Bernstein SL, Baker NL, Tanner N, Carpenter MJ, Cummings KM, Silvestri G, Toll BA. Nicotine replacement therapy starter packs and gain-framed messages to promote smoking cessation in lung cancer screening: a randomized trial. Am J Respir Crit Care Med. 2026 Jun 1;212(6):1170-1173. PubMed Central PMCID: [PMC13253041](https://pubmed.ncbi.nlm.nih.gov/PMC13253041/).
2. Hatsukami DK, Goniewicz ML, Leischow SJ, Rigotti NA, Tellman TV, Warren NJH, Davidson BA, Toll BA. An AACR Policy Statement to Support a Federal Limit on Nicotine in Combustible Tobacco and Protect Public Health. Clin Cancer Res. 2026 Jan 6;32(1):16-26. PubMed PMID: [41195890](https://pubmed.ncbi.nlm.nih.gov/41195890/).
3. Fathi JT, Cinciripini PM, DePrimo MJ, Houston TP, Kathuria H, Park ER, Pua BB, Roelke TM, Taylor KL, Toll BA, Zeliadt S, Kazerooni EA, Smith RA, Ostroff JS. The American Cancer Society National Lung Cancer Roundtable strategic plan: Tobacco treatment in the context of lung cancer screening. Cancer. 2025 Sep 15;131(18):e35972. PubMed PMID: [40928189](https://pubmed.ncbi.nlm.nih.gov/40928189/).
4. Palmer AM, DeMass R, Rojewski AM, Bagley EM, Carpenter MJ, Smith TT, Toll BA. Augmented Doses of Nicotine Replacement Therapy: Feasibility for Dual Cigarette and E-Cigarette Cessation. Am J Prev Med. 2025 Aug;69(2):107664. PubMed Central PMCID: [PMC13430507](https://pubmed.ncbi.nlm.nih.gov/PMC13430507/).
5. Palmer AM, Smith TT, Chen AA, Rojewski AM, Carpenter MJ, Toll BA. Nicotine Pouch Use in Youths and Adults Who Use

Cigarettes, E-Cigarettes, and Smokeless Tobacco. JAMA Netw Open. 2025 May 1;8(5):e2511630. PubMed Central PMCID: [PMC12070233](#).

Other Significant Products Highlighting Contributions to Science

1. Sanford BT, Brownstein NC, Baker NL, Palmer AM, Smith TT, Rojewski AM, Toll BA. Shift From Smoking Cigarettes to Vaping Nicotine in Young Adults. JAMA Intern Med. 2024 Jan 1;184(1):106-108. PubMed Central PMCID: [PMC10644245](#).
2. Toll BA, Smith TT, King BA. Nicotine e-cigarettes: considerations for healthcare providers. Nat Med. 2024 Jun;30(6):1513-1514. PubMed PMID: [38627561](#).
3. Cartmel B, Fucito LM, Bold KW, Neveu S, Li F, Rojewski AM, Gueorguieva R, O'Malley SS, Herbst RS, Toll BA. Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening. J Thorac Oncol. 2024 Apr;19(4):643-649. PubMed Central PMCID: [PMC10999350](#).
4. Fucito LM, Baldassarri SR, Baker NL, Palmer AM, O'Malley SS, Carpenter MJ, Krishnan-Sarin S, Gray KM, Toll BA. Varenicline for E-Cigarette Cessation in Adults: A Preliminary Placebo-Controlled Randomized Trial. Am J Prev Med. 2024 Aug;67(2):296-298. PubMed Central PMCID: [PMC11260542](#).
5. Palmer AM, Rojewski AM, Carpenter MJ, Klemperer EM, Baker NL, Sanford BT, Toll BA. Interest in quitting e-cigarette use by device type and smoking history in US adults. Tob Control. 2024 Jun 20;33(4):537-540. PubMed Central PMCID: [PMC10350465](#).

Certification:

I certify that the information provided is current, accurate, and complete. This includes, but is not limited to, information related to current, pending, and other support (both foreign and domestic) as defined in 42 U.S.C. § 6605.

In accordance with Section 10632 of the CHIPS and Science Act of 2022 (42 U.S.C. § 19232), each individual identified as a senior/key person must certify that they are not a party to a malign foreign talent recruitment program.

Research Security Training Requirement for Federal Award Personnel: In accordance with Section 10634 of the CHIPS and Science Act of 2022 (42 U.S.C. § 19234), each individual identified as a senior/key person must certify that they have completed the requisite research security training that meets the requirements specified in Item 2 of Important Notice No. 149 within 12 months prior to proposal submission.

Misrepresentations and/or omissions may be subject to prosecution and liability pursuant to, but not limited to, 18 U.S.C. §§287, 1001, 1031 and 31 U.S.C. §§3729-3733 and 3802.

Certified by Toll, Benjamin in SciENcv on 2026-08-18 17:40:05

NIH BIOGRAPHICAL SKETCH SUPPLEMENT

Name: Toll, Benjamin

Persistent Identifier (PID) of the Senior/Key Person: <https://orcid.org/0000-0001-7978-8416>

Position Title: Oliver S. and Jennie R. Donaldson Charitable Trust Endowed Chair in Cancer Research

Organization and Location: MUSC Hollings Cancer Center, Charleston, South Carolina, United States

Personal Statement

As the Oliver and Jennie Donaldson Endowed Chair in Cancer Research and Professor of Public Health Sciences and Psychiatry at the Medical University of South Carolina (MUSC), Associate Director of Education and Training (i.e., AD of CRTEC) for the Hollings Cancer Center (HCC), the Co-Director of Lung Cancer Screening Program at HCC, and the Director of the Tobacco Treatment Program at MUSC, I lead a treatment team focused on preventing cancer through provision of tobacco treatment for all HCC/MUSC patients who smoke. I have been conducting tobacco cessation research for over 20 years, having completed 8 large scale randomized smoking cessation clinical trials as PI and multiple pilot clinical trials. I have received continuous funding for over 20 years from both the National Cancer Institute (R01CA296186, R01CA251158, R01CA207229, P50CA196530 [R01 equivalent], R01CA140256, R21CA181471, R21CA181569, R21CA127818) and the National Institute on Drug Abuse (P50DA036151, K12DA000167) to conduct this research. Two of my large NCI R01 funded clinical trials are currently running - the first is a recently funded trial investigating varenicline tartrate for cessation of e-cigarette use and the second is a trial comparing contingency management added to counseling and NRT for smoking cessation among pre-surgical cancer patients, in addition to being a Co-Investigator on multiple additional clinical trials. Moreover, I am a frequent leader or author of clinical practice guidelines or policy statements for major US medical societies (e.g., American Association for Cancer Research [AACR], American Society of Clinical Oncology [ASCO], American College of Chest Physicians [CHEST]). As part of the AACR Cancer Centers Alliance, I serve as the Chair of the AD - CRTEC Steering Committee, which is a national initiative to assist with CRTEC initiatives and trainings in the US. In my role as Associate Director of Education and Training at the MUSC Hollings Cancer Center I coordinate and direct all of our oncology-oriented education and training. This includes oversight and facilitation of multiple training grants, education to healthcare professionals across South Carolina, and centralized assessment, tracking, and mentoring of all of our HCC trainees. I have served as an Associate Director of a T32 training grant, serve as Associate Director of the ACS-IRG training grant, and mentored a K07 mentee (Dr. Alana Rojewski who was awarded multiple NCI R01 grants), a K12 mentee (Dr. Amanda Palmer who was awarded an ACS IRG grant), 8 T32 postdoctoral fellows (across a variety of T32 grants), 39 pre-doctoral psychology interns, and 9 MPH capstone students, all of which has resulted in 57 publications in peer reviewed journals led by trainees as first author. Thus, I have a long history of continuous NCI funding, extensive experience in training and mentoring, and a long history of productive mentorship, including transitioning two K mentees to their first R01. Thus, I have the requisite experience and track record to serve as a Co-Mentor for Dr. Smith's K23. I look forward to contributing to the success of this training program.

Honors

2026	Board Certification in Addiction Psychology, American Board of Professional Psychology
2025 - 2026	Chair, Steering Committee for AACR Cancer Centers Alliance Associate Directors for Cancer Research Training and Education Coordination (CRTEC), American Association for Cancer Research (AACR)
2024	SRNT Fellow, Society for Research on Nicotine & Tobacco (SRNT)
2023 - 2026	SRNT President-Elect, President, Past President, Society for Research on Nicotine & Tobacco (SRNT)
2022 - 2026	Co-Chair, Clinical Practice Guideline for Tobacco Treatment for Hospitalized Inpatients, American College of Chest Physicians (CHEST)
2019 - 2022	Board Member (At-Large Member Delegate), Society for Research on Nicotine & Tobacco (SRNT)
2015	Psychologist License Number 1349, State of South Carolina
2011 - 2026	Member, American Association for Cancer Research Tobacco and Cancer Subcommittee, American Association for Cancer Research (AACR)

Contributions to Science

1. I am a national leader for tobacco treatment research, clinical care, and tobacco regulatory science, having served on numerous

US medical association policy and clinical practice guideline statements. I worked on joint policy statements by the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) regarding e-cigarettes that was initially published in 2015 and then updated in 2022. I also led a policy statement by ATTUD and SRNT encouraging pairing of tobacco treatment with lung cancer screening. Most recently, I am co-chairing a new clinical practice guideline for the American College of Chest Physicians (CHEST) regarding tobacco treatment for hospitalized patients who smoke, and this ongoing project is at the stage of manuscript writing. I am an author on the American Thoracic Society's clinical guideline for pharmacologic treatment for people who smoke. As part of the AACR subcommittee on Tobacco and Cancer, I led the effort for an official policy statement of the AACR advocating for assessment and treatment of tobacco use by cancer patients. In this paper, we encourage all oncology providers to assess and intervene with patients' tobacco use, in both clinical and research venues. This is the first statement of AACR to publicly suggest that all oncologists intervene with tobacco.

2. Many of my publications have evaluated gain- and loss-framed messaging in clinical populations. Of note, my review on the evolution on clinician messaging to improve tobacco cessation was part of a special issue of Clinical Cancer Research (Impact factor=10.2), which is the premier clinical journal for the American Association for Cancer Research (AACR), the largest and oldest organization in America devoted to cancer research. This special issue was celebrating the 50th anniversary of the Surgeon General's Report on Tobacco and Health. I provided evidence that oncologists should present their smoking cessation messages in a gain-framed manner.
3. I am an expert on interest in quitting and population-based trends in non-combusted tobacco use in large nationally representative datasets, and I and my team of collaborators have published several important clinical trials showing the first evidence regarding the types of treatments that help with e-cigarette cessation. Recently, I published results of several large studies using the US FDA Population Assessment of Tobacco and Health (PATH) study, showing that: 1) a large number of adolescents and adults are using nicotine pouches (e.g., ZYN) in the US, 2) there are now more never-smoking e-cigarette users in the key demographic of 18-24 year olds than established cigarette users in the US, and 3) well over 60% of e-cigarettes users want and plan to quit vaping (with data published in the prestigious journals JAMA Network Open, JAMA Internal Medicine and BMJ's Tobacco Control).

Certification:

I certify that the information provided is current, accurate, and complete. This includes, but is not limited to, information related to current, pending, and other support (both foreign and domestic) as defined in 42 U.S.C. § 6605.

In accordance with Section 10632 of the CHIPS and Science Act of 2022 (42 U.S.C. § 19232), each individual identified as a senior/key person must certify that they are not a party to a malign foreign talent recruitment program.

Research Security Training Requirement for Federal Award Personnel: In accordance with Section 10634 of the CHIPS and Science Act of 2022 (42 U.S.C. § 19234), each individual identified as a senior/key person must certify that they have completed the requisite research security training that meets the requirements specified in Item 2 of Important Notice No. 149 within 12 months prior to proposal submission.

Misrepresentations and/or omissions may be subject to prosecution and liability pursuant to, but not limited to, 18 U.S.C. §§287, 1001, 1031 and 31 U.S.C. §§3729-3733 and 3802.

Certified by Toll, Benjamin in SciENcv on 2026-08-1817:40:05